Refracture of the cemented vertebrae after percutaneous vertebroplasty: risk factors and imaging findings

Yu-chao Xiong1†, Wei Guo2†, Fan Xu1, Ci-ci Zhang1, Zhi-ping Liang1, Li Wu1, Song Chen1 and Xu-wen Zeng1*

Abstract

Background: To determine the related imaging findings and risk factors to refracture of the cemented vertebrae after percutaneous vertebroplasty (PVP) treatment.

Methods: Patients who were treated with PVP for single vertebral compression fractures (VCFs) and met this study’s inclusion criteria were retrospectively reviewed from January 2012 to January 2019. The follow-up period was at least 2 years. Forty-eight patients with refracture of the cemented vertebrae and 45 non-refractured patients were included. The following variates were reviewed: age, sex, fracture location, bone mineral density (BMD), intravertebral cleft (IVC), kyphotic angle (KA), wedge angle, endplate cortical disruption, cement volume, surgical approach, non-PMMA-endplate-contact (NPEC), cement leakage, other vertebral fractures, reduction rate (RR), and reduction angle (RA). Multiple logistic regression modeling was used to identify the independent risk factors of refracture.

Results: Refracture was found in 48 (51.6%) patients. Four risk factors, including IVC ($P = 0.005$), endplate cortical disruption ($P = 0.037$), larger RR ($P = 0.007$), and NPEC ($P = 0.006$) were found to be significant independent risk factors for refracture.

Conclusions: Patients with IVC or larger RR, NPEC, or endplate cortical disruption have a high risk of refracture in the cemented vertebrae after PVP.

Keywords: Vertebroplasty, Risk factors, Magnetic resonance imaging, Spinal fractures, Bone cements

Background

Percutaneous vertebroplasty (PVP) is a minimally invasive technique for the treatment of vertebral compression fractures (VCFs). Most clinical studies [1–5] have reported that this treatment can provide immediate pain relief and biomechanical stability, and restore partial vertebral height. Despite these excellent clinical results, complications such as cement leakage, infection, embolism, fractures in the adjacent vertebrae, and refracture of previously treated vertebrae have been reported [6–10]. However, recompression in cemented vertebrae may lead to aggravation of the kyphotic deformity, vertebral height loss, and even compression of the spinal cord by vertebral body fracture, which usually requires further treatment [8, 9]. Some researchers [8, 11, 12] believe that cement distribution patterns may be an important predisposing factor to refracture. Kim [13] reported that the intravertebral cleft (IVC) might be a significant risk factor. Although research has highlighted many risk factors, refracture of the cemented vertebrae remains a controversial topic.
The treatment of refracture in cemented vertebrae remains challenging. The treatment strategy for vertebral fractures need to be changed when the risks of PVP outweighs the efficacy. Thus, the purpose of this study was to assess the related imaging findings and risk factors of patients who experienced refracture of the cemented vertebrae after PVP.

Methods

Patient selection
This retrospective cohort study was conducted from January 1, 2012 to January 1, 2019 in the spine surgery department of our hospital. The research program was approved by Institutional Review Board of Guangzhou Red Cross Hospital, and all procedures were performed according to the Declaration of Helsinki. All patients received written informed consent before operation.

A total of 1303 patients who were diagnosed with VCF (T4-L5) receiving single level PVP were enrolled in this study. Patients who met the following criteria were excluded:

(i) pathological vertebral fractures secondary to tumor, severe inflammation, or long-term corticosteroid use;
(ii) patients without available radiographs or magnetic resonance imaging (MRI);
(iii) No history of PVP surgery;
(iv) patients with neurologic deficits;
(v) follow-up time less than 24 months;
(vi) patients with hyperparathyroidism, hyperthyroidism, or other bone metabolic diseases.

The inclusion criteria were as follows:

(i) patients who had plain films preoperatively, immediately after surgery, and at the final follow-up;
(ii) patients who underwent MRI preoperatively and at last follow-up;
(iii) follow-up period of at least 2 years;
(iv) patients with a bone density scan before the PVP;
(v) single-level symptomatic VCF treated with PVP;

Based on these criteria, a total of 93 patients were enrolled in our study (75 women, 18 men).

Operative procedure
All patients received bilateral or unilateral PVP in the prone position under the guidance of C-arm fluoroscopy after local anesthesia (1% lidocaine). According to Jensen's technique [14], under C-arm fluoroscopic control, 11-gauge or 13-gauge bone biopsy needles were entered the pedicle in a slightly descending manner or parallel to the superior and inferior edges of the pedicle. The needle was positioned in the optimal position as confirmed by C-arm, that is, the tip reached the anterior third of the vertebral body and the middle height of the midline. After the stylet was removed from the trocar, a formulated polymethylmethacrylate (PMMA) mixture was instilled, filling the fractured bone. The cement injection process was performed slowly, and strictly monitored under C-arm fluoroscopy in the lateral plane to avoid cement leakage. The bone cement filled the fractured vertebrae in the anterior third of the vertebral body as much as possible to form an effective mechanical column. The injection was immediately stopped when cement leakage was seen in the segmental vein, adjacent intervertebral disk, epidural space, or epidural vein. After PVP, all patients were allowed to ambulate the day after surgery.

Imaging examinations
Prior to PVP and at least 24 months of follow-up, all patients underwent spinal MR examinations of the spine supine position. The MR examinations were performed with a 1.5-T (Siemens Avanto) imager with the following sequences: a sagittal T1-weighted spin-echo sequence (TR, 535 ms; TE, 11 ms), a sagittal T2-weighted spin-echo sequence (TR, 3500 ms; TE, 90 ms), and a spectral attenuated inversion recovery (SPAIR) sequence (TR, 3500 ms; TE, 90 ms). Prior to PVP and within 2 weeks of PVP and following underwent anteroposterior and lateral radiographs of the spine supine position.

Radiological assessment
All images were analyzed during a time span of 2 weeks. Images were randomly evaluated by two experienced musculoskeletal radiologists in a random order, each blinded to the clinical information. In our study, the inter observer correlation coefficient (ICC) of all radiology parameters was excellent (ICC > 0.85). A consensus was reached when two observers disagreed on the first reading. Face-to-face training was conducted before the study.

Anatomical locations of the involved vertebrae
The anatomical locations of the involved vertebrae were divided into two groups: vertebrae outside the thoracolumbar junction (from T4 to T9 or L3 to L5) and vertebrae at the thoracolumbar junction (from T10 to L2) [15].

Intravertebral cleft (IVC)
The IVC was detected as an area of signal loss (gas-containing space) or showing marked hyperintensity (fluid collection) on the preoperative sagittal T2-weighted images [15, 16].
Endplate cortical disruption
Endplate cortical disruption was determined as evident discontinuation in the cortical endplate as seen on the preoperative sagittal T2/T1-weighted images [17].

Kyphotic angle (KA) (Cobb’s angle) and reduction angle (RA)
KA was defined as the angle between the upper endplate of the upper vertebra and the lower endplate of the lower vertebra. At L5, the KA was defined as the angle between the upper endplate of L4 and the upper endplate of the sacral vertebra. RA was calculated as the difference between preoperative and immediate postoperative KA [18].

Wedge angle (WA)
WA was defined as the angle between the upper endplate line and the lower endplate of the fractured vertebra.

Vertebral compression rate (CR), reduction rate (RR) and compression rate increase (CRI) (Fig. 1)
CR refers to the ratio of vertebral height of the fractured vertebrae to the average vertebral height of the upper and lower vertebrae at the same site [18]. At L5, CR was the ratio of L4 vertebral height to L5 vertebral height at the same site. RR was calculated as the difference between preoperative and immediate postoperative CR [18]. CRI was defined as the difference in CR between immediately after surgery and the last follow-up.

Cement leakage
Cement leakage was defined as any cement present in the space beyond the cortical margin [19].

Non-PMMA-endplate-contact (NPEC)
NPEC was defined as postoperative plain radiographs showing that the injected PMMA did not come into contact with the upper and lower endplates [20]. The patterns of NPEC were classified as NPEC on the upper endplate, NPEC on the lower endplate, NPEC on the upper and lower endplates, and no NPEC on anteroposterior and lateral radiography of the treated vertebra [21].

Clinical data analysis
The medical records were retrospectively analyzed to collect the use of anti-osteoporosis drug. Medicament for the treatment of osteoporosis include zoledronic acid, calcium and vitamin D supplements. Effective anti-osteoporosis therapy needs to meet the minimum drug ownership rate of 80% within 6 months [22]. Patient demographics, including gender, age, interval (the period between the start of new back pain related to MRI-confirmed fracture and the time of PVP), other vertebral fractures, surgical approach, bone mineral density (BMD), and cement volume were also analyzed.

Statistical analysis
All statistical analyses were performed using statistics software (SPSS, Chicago, IL, USA). P < 0.05 indicated a statistically significant difference. Logistic regression univariate and multivariate analyses were used to assess the risk factors for refracture of the cemented vertebrae after PVP. The possible risk factors with P value less than or equal to 0.10 in univariate analysis were input into the final multivariate logistic regression model. After adjusting other risk factors, the significance of each risk factor on refracture was tested.

Results
In total, 93 patients (refracture group, n = 48; non-refracture group, n = 45) were reviewed. Patients in the refracture group were followed for 1.2–25.9 months (mean, 9.3 months; median, 11.2 months). In the refracture group,
the CRI was 15.1–40.2% (mean, 23.87%; standard deviation (SD), 7.89%). Patients in the non-refracture group were followed for 24.8–46.6 months (mean, 33.2 months; median, 38.4 months).

Univariate analysis revealed that IVC (P < 0.001), endplate cortical disruption (P = 0.026), reduction rate (P < 0.001), NPEC (P < 0.001), and kyphotic angle (P = 0.014) were significant factors for refracture of the cemented vertebrae after PVP (Table 1). On multivariate analysis, however, IVC (P = 0.005; odds ratio, 27.12; 95% confidence interval [CI]: 2.67, 275.38), endplate cortical disruption (P = 0.037; odds ratio, 3.23; 95% confidence

| Table 1 | Univariate analysis: clinical factors and imaging finds in the refracture and non-refracture groups |
|---------|-------------------------------------------------------------------------------------------------|
| clinical factors and imaging finds       | Refracture(n = 48) | Non-refracture(n = 45) | P value |
| Age (years)                              | 79.65 ± 7.90       | 78.29 ± 7.21            | 0.303   |
| Gender                                   |                     |                         |         |
| Men                                      | 8                    | 10                      |         |
| Women                                    | 40                   | 35                      | 0.498   |
| Fracture location                        | 33                   | 36                      |         |
| Thoracolumbar                            | 15                   | 9                       | 0.215   |
| Non-thoracolumbar                       | 0.664 ± 0.15         | 0.73 ± 0.16             | 0.686   |
| BMD(g/cm²)                               | 17.56 ± 9.51         | 12.58 ± 9.64            | 0.014   |
| kyphotic angle (°)                       | 10.88 ± 6.22         | 10.20 ± 5.01            | 0.204   |
| Wage angle (°)                           | 2.15                 | 1.95                    | <0.001  |
| IVC                                      | 18                   | 1                       |         |
| Present                                  | 30                   | 44                      |         |
| Absent                                   | 27                   | 15                      | 0.026   |
| Endplate cortical disruption             | 15                   | 9                       |         |
| Present                                  | 21                   | 30                      |         |
| Absent                                   | 1.3 ± 0.709          | 3.01 ± 0.663            | 0.440   |
| Bone cement volume (ml)                  | 3.13 ± 0.709         | 3.01 ± 0.663            |         |
| Surgical approach                        | 5                    | 4                       |         |
| Left                                     | 38                   | 39                      |         |
| Right                                    | 2.15                 | 1.95                    | <0.001  |
| Bilateral                                | 14                   | 7                       |         |
| NEPC                                     | 2.15                 | 1.95                    |         |
| Present on lower endplate                | 14                   | 7                       |         |
| Present on upper endplate                | 7                    | 10                      |         |
| Present on upper and lower endplate      | 26                   | 16                      |         |
| Absent                                   | 12                   | 12                      | <0.001  |
| Leakage of bone cement                   | 13                   | 9                       |         |
| Present                                  | 35                   | 36                      | 0.423   |
| Absent                                   | 11                   | 11                      | 0.134   |
| other vertebral fractures                | 8                    | 5                       | 0.134   |
| Adjacent vertebral fracture              | 21                   | 11                      |         |
| Non-adjacent vertebral fracture          | 19                   | 29                      |         |
| Reduction rate (%)                       | 11.92 ± 11.18        | 4.44 ± 5.18             | <0.001  |
| Reduction angle (°)                      | 4.02 ± 3.89          | 4.76 ± 6.28             | 0.491   |
| Effect anti-osteoporotic therapy         | 34                   | 33                      | 0.486   |
| Yes                                      | 14                   | 12                      |         |
interval (CI): 1.07, 9.75), larger RR (P = 0.007; odds ratio, 2.94; 95% confidence interval [CI]: 1.33, 6.47), and NPEC (P = 0.006; odds ratio, 1.99; 95% confidence interval [CI]: 1.23, 3.24) showed significance after adjustment for other variables (Table 2).

Analysis of the relationship between endplate cortical disruption and the displacement of the anterior edge of the vertebral body found that the anterior movement of the vertebral body was 3.12 ± 2.62 mm for with endplate cortical disruption, and 1.67 ± 2.18 mm for without endplate cortical disruption (P < 0.05).

**Discussion**

Researchers have not uniformly described the loss of vertebral height and the criteria for unified diagnosis of height loss in cemented vertebrae after PVP. He [12] and Kim [20] described ‘recompression’ of previously treated vertebrae. The term ‘recompression’ might be confused with additional loss of vertebral height, including osteoporosis [23]. Heo [9] and Yu [18] reported using recollapse to describe the loss of the same vertebrae after PVP. The term ‘recollapse’ might be misunderstood cement block cracked [12]. In the present study, there was vertebral bone marrow edema, and the loss of vertebral height only in the bony vertebra, not in the cement mass. For these reasons, we recommend using the term ‘refracture’ to describe this condition. In previous studies, recompression or refracture of augmented vertebrae were defined as a height reduction of 1 mm or 4 mm on follow-up radiographs [12, 15, 20, 24–27]. Due to the magnification ratio on radiographs, the measurement of height loss can easily lead to incorrect evaluation. In addition, several long-term studies of patients who were post-vertebral augmentation have showed that in up to 30% of patients have a gradual decrease in vertebral body height of 10 to 15% after PVP between 12 and 24 months [28]. Thus, in this study, the criterion of 15% decrease in height [18] and presence of vertebral bone marrow edema was adopted.

Although the risk factors for refracture in cemented vertebrae after PVP have been previously reported [8, 11], to our knowledge this is the first study to report the risk factors and imaging findings of refracture based on bone marrow edema as a diagnostic basis.

The incidence of refracture in cemented vertebrae was 3.68%(48/1303) in this study, which was approximately consistent with the findings in previous studies, which ranged from 0.56 to 27.63% [8, 9, 18, 24, 29]. However, the author infers that the true incidence of refractures should be higher than the expected data in the present study. This is because some patients with refracture did not seeking medical services and the present study used rigorous inclusion and exclusion criteria and grouping criteria.

**Table 2** Outcome of multivariate logistic regression analysis

|                          | OR (95% CI) | P value |
|--------------------------|-------------|---------|
| Endplate cortical disruption | 3.23 (1.07–9.75) | 0.037   |
| IVC                      | 27.12 (2.67–275.38) | 0.005   |
| RR (%)                   | 2.94 (1.33–6.47) | 0.007   |
| NPEC                     | 1.99 (1.23–3.24)  | 0.006   |

Data were analyzed with logistic regression. Multivariable analysis adjusted for Endplate cortical disruption, IVC, RR, and NPEC

CI: Confidence interval, OR: Odds ratio

Fig. 2 An 82-year-old woman with refracture after PVP. MRI and lateral plain X-ray of an 82-year-old woman with a T11 compression fracture. a Sagittal SPAIR showed a T11 compression fracture with bone marrow edema, IVC (black arrow), and endplate cortical disruption (white arrow). b Postoperative X-ray showed the cemented vertebrae with NPEC on the lower endplate (black arrow) and displacement of the anterior edge of the vertebral body (white arrow). c d MRI and lateral X-ray at 5 months after PVP showed loss of height of T11 and bone marrow edema
We evaluated the risk factors for refracture in cemented vertebrae. IVC showed a statistically significant relationship to refracture (Table 2), which corresponds with many previous studies [8, 9, 11, 18, 30, 31]. IVC is a risk factor for refracture in cemented vertebrae and can be explained by two factors; namely, the IVC factor and secondary changes caused by IVC.

With regard to the IVC factor, IVC provides radiological evidence of osteonecrosis [29, 32, 33]. Osteonecrosis of the involved vertebrae would progress after PVP, which would eventually weaken the structural rigidity of the vertebral body and result in refracture of the remainder of the vertebral body (Figs. 2 and 3) [9]. In addition, the fractured vertebrae with IVC was usually a solid lump caused volumetric pressure effect that may aggravate the process of osteonecrosis [9]. Heo et al. [9] also reported that the timing of PVP is of great importance for patients with IVC, given that it is likely unfavorable during the early phase of osteonecrosis. Premature PVP may cause collateral vessels in necrotic bone to fail to form.

With regard to secondary changes caused by the IVC factor, IVC was related to cement distribution pattern [9, 12, 18] and vertebral height restoration [34].

When bone cement is injected, it often enters the low-pressure zone (IVC zone), which causes the bone cement to form solid lump cement, making it easier to form NPEC (Fig. 2). In our study, the incidence of NPEC was significantly higher in patients with IVC (94.74%) than without IVC (78.38%). Further analysis also indicated that NPEC was a risk factor associated with refracture (Table 2). Zhang [24] found that patients without NPEC had a lower risk of recompression compared with patients with NPEC on the upper and lower endplates. Hou [25] found that the smaller the distance between PMMA and the endplate, the lower the incidence of recompression. Heo [20] found that recompression occurred in unsupported areas of PMMA. Our findings are consistent with previous research. Bone cement is in contact with both the upper and lower endplates, so it can provide a better support in the vertical direction since the load is transmitted through both the upper and lower endplates, which are harder in nature. When bone cement had NPEC, the load did not transmitted through the cementless area, resulting in a stress shielding effect, so the bone cement may serve to concentrate stress on the surrounding fragile bones and lead to refracture.

In our study, compared with the VCFs without IVC, the height of the vertebral body with IVC increased from 7.19 to 12.63%. Michael [34] also reported that vertebroplasty increased the height of the fractured vertebrae, and these effects were most remarkable in fractured vertebrae with IVC. Further analysis indicated that RR was

Fig. 3 A 59-year-old man with refracture after PVP. Preoperative T2W and SPAIR images (a, b) showed a T10 compression fracture with IVC. Postoperative lateral radiographs (c) after 2 days showed NPEC on the lower and upper endplates. The T2WI, SPAIR image, and lateral radiograph 5 months after PVP (d-f) showed refracture of the cemented T10 vertebra with loss of height and bone marrow edema.
a risk factor associated with refracture (Table 2). Lin [11] also found that cemented vertebrae with significant vertebral height restoration after PVP were prone to refracture. Too much recovery of the vertebral body may lead to increased tension of the paravertebral soft tissue, which may lead to increased mechanical load on the enlarged vertebrae or more unstable fractures. Consequently, the risk of refracture of involved vertebrae increased with a greater degree of height restoration.

Overall, IVC affected RR and NPEC, but RR and IVC were not all dependent on the impact of IVC. The NPEC, IVC, and RR were independent risk factors for refracture in cemented vertebrae after PVP.

In our study, endplate cortical disruption was also an independent risk factor for refracture in cemented vertebrae after PVP (Table 2) (Fig. 4). We explained the occurrence of refracture after PVP as a biomechanical model (Fig. 5). When there is endplate cortical disruption, the anterior edge of the vertebral body will move forward in the process of bone cement injection (Fig. 2). Anterior vertebral displacement causes two consequences. On one hand, the axial force of the vertebral body will be partially dispersed laterally, and the vertebral body is weak against lateral pressure. On the other hand, the fractured vertebral body cannot be sufficiently filled with bone cement, because the displacement of the anterior edge of the vertebral body can offset the force of the bone cement to diffuse into the trabecular bone. As a result, the cemented vertebrae with endplate cortical disruption is more vulnerable to refracture.

Previous research found that BMD was a risk factor for refracture after surgery [31, 35–37]. However, in our study BMD was not a risk factor for refracture. We speculate that this is due to the fact that this study used bone marrow edema as a diagnostic criterion for refracture. Villarraga [37] found that the loss of height in cemented vertebrae was the natural development of osteoporosis concluded from finite element model analysis, so the loss of height in cemented vertebrae caused by osteoporosis may not cause bone marrow edema.

Although some studies [1–5] reported that PVP could provide significantly pain relief in patients with VCFs, more and more studies [38, 39] does not support significant clinically benefits from PVP compared with placebo. Refracture in cemented vertebrae may be one of the reasons why pain relief is not better than placebo. In our opinion, looking for strategies for poor clinical effects of PVP provides clinicians with a pragmatic method of how to best treat patients.

This study had several limitations. First, it was a retrospective study with a single center and relatively small sample size, and a prospective, multi-center studies with...
a larger sample size are required to ensure the universality of our conclusions. Second, two-dimensional X-ray was used to determine the NPEC. In these images, NPEC may be underestimated. To accurately assess NPEC, three-dimensional CT scans will help. Finally, although there is no significant difference in effective anti-osteoporosis therapy between the refracture group and the non-refracture group, a large proportion of patients receiving effective anti-osteoporosis treatment in this study may lead to bias.

Conclusions
Four independent risk factors were significantly associated with refracture of the cemented vertebrae after PVP, including intravertebral cleft, non-PMMA-endplate-contact, increased reduction rate, and endplate cortical disruption. Therefore, the current surgical methods and treatment strategies may need to be adjusted on the basis of the risk factors of patients.

Abbreviations
PVP: Percutaneous vertebroplasty; VCFs: Vertebral compression fractures; BMD: Bone mineral density; IVC: Intravertebral cleft; KA: Kyphotic angle; NPEC: Non-PMMA-endplate-contact; RR: Reduction rate; RA: Reduction angle; PMMA: Polymethylmethacrylate; MRI: Magnetic resonance imaging; WA: Wedge angle; CR: Compression rate; CRI: Compression rate increase; CI: Confidence interval

Acknowledgments
We thank Peter Mittwede, MD, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript. We thank Dr. Yahui Liu for helping with the drawing of this article.

Authors’ contributions
X.W.Z, Y.C.X and W. G were responsible for the study concept design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for intellectual content. X.W.Z, Y.C.X and F. X conducted data analyses and all the authors contributed to the interpretation of data. Z.P.L and S. C were responsible for the analysis and interpretation of data. L. W and C.C.Z conducted data collection and performed preliminary data preparations. All authors read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by Ethics Committee of Guangzhou Red Cross Hospital (reference number 2020/125/02). In this retrospective study, written informed consent was obtained from all patients included in this study.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Author details
1Department of Radiology, Guangzhou Red Cross Hospital, Jinan University, 396 Tongfu Road, Guangzhou 510220, Guangdong Province, China. 2Department of Radiology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, 241 Liuyang Road, Wuhan 430063, Hubei Province, China.

Received: 27 December 2020 Accepted: 11 May 2021
Published online: 19 May 2021

References
1. Anderson PA, Froyshteter AB, Tontz WL Jr. Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures. J Bone Miner Res. 2013;28(2):372–82. https://doi.org/10.1002/jbmr.1762.
2. Clark W, Bird P, Gonski P, Diamond TH, Smerdely P, McNeil HP, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10052):1408–16. https://doi.org/10.1016/S0140-6736(16)31341-1.
3. De Leacy R, New, high-quality evidence for Vertebroplasty in the Management of Painful Recent Compression Fractures: review of the VAPOUR trial. World Neurosurg. 2016;96:596–8. https://doi.org/10.1016/j.wneu.2016.09.043.
4. Klazen CA, Lohle PN, de Vries J, Janssen FH, Tielliebek AV, Blonk MC, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet. 2010;376(9746):1085–92. https://doi.org/10.1016/S0140-6736(10)60554-3.

5. Masala S, Mastaarergil R, Petrella MC, Massari F, Ursone A, Simonetti G. Percutaneous vertebroplasty in 1,253 levels: results and long-term effectiveness in a single Centre. Eur Radiol. 2009;19(9):1165–71. https://doi.org/10.1007/s00330-008-1133-4.

6. Kim YJ, Lee JW, Park KW, Yeon JS, Jeong HS, Park JM, et al. Pulmonary cement embolism after percutaneous vertebroplasty in osteoporotic vertebral compression fractures: incidence, characteristics, and risk factors. Radiology. 2009;251(1):250–9. https://doi.org/10.1148/radiol.2511080854.

7. Schmid KE, Boszczyk BM, Bierschneider M, Zarfl A, Robert B, Jaksha H. Spondylitis following vertebroplasty: a case report. Eur Spine J. 2005;14(9): 895–9. https://doi.org/10.1007/s00586-005-0905-7.

8. Kang SK, Lee CW, Park NK, Kang TW, Lim JW, Cha KY, et al. Predictive risk factors for refracture after percutaneous vertebroplasty. Ann Rehabil Med. 2011;35(6):844–51. https://doi.org/10.5535/arm.2011.35.6.844.

9. Heo DH, Chin DK, Yoon YS, Kuh SU. Recollapse of previous vertebral compression fracture after percutaneous vertebroplasty. Osteoporosis Int. 2009;20(3):473–80. https://doi.org/10.1007/s00198-008-0862-3.

10. Suzuk N, Ogikubo O, Hansson T. Previous vertebral compression fractures add to the deterioration of the disability and quality of life after an acute compression fracture. Eur Spine J. 2010;19(4):567–74. https://doi.org/10.1007/s00586-009-1162-9.

11. Lin WC, Lee YC, Lee CH, Kuo YL, Cheng YF, Lui CC, et al. Recurrences in cemented vertebrae after percutaneous vertebroplasty: a retrospective analysis. Eur Spine J. 2008;17(4):592–9. https://doi.org/10.1007/s00586-007-0564-y.

12. He D, Lou C, Yu W, Zhu K, Zhu W, Liu F, et al. Cement distribution patterns are associated with recompression in cemented vertebrae after percutaneous Vertebroplasty: a retrospective study. World Neurosurg. 2018;120:e1. https://doi.org/10.1016/j.wneu.2018.06.113.

13. Kim YJ, Lee JW, Kim KJ, Chung SK, Kim HJ, Park JM, et al. Percutaneous vertebroplasty for intravertebral cleft: analysis of therapeutic effects and outcome predictors. Skelet Radiol. 2010;39(8):757–66. https://doi.org/10.1007/s00256-009-0866-8.

14. Jensen ME, Evans AJ, Mathis JM, Kalmiss DF, Clot HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol. 1997;18(10):1897

15. Lin WC, Lu CH, Chen HL, Wang HC, Yu CY, Wu RW, et al. The impact of preoperative magnetic resonance images on outcome of cemented vertebrae. Eur Spine J. 2010;19(11):1899–905. https://doi.org/10.1007/s00586-010-1434-6.

16. Wu AM, Chi YL, Wu WF. Vertebral compression fracture with intravertebral cleft sign: pathogenesis, image, and surgical intervention. Asian Spine J. 2013;7(2):148–55. https://doi.org/10.4184/asj.2013.7.2.148.

17. Hou Y, Yao Q, Zhang G, Ding L, Huang H. Polymethylmethacrylate distribution is associated with recompensation after vertebroplasty or kyphoplasty for osteoporotic vertebral compression fractures: a retrospective study. PLoS One. 2018;13(6):e0198407. https://doi.org/10.1371/journal.pone.0198407.

18. McKiernan F, Faciszewski T, Jensen R. Reporting height restoration in vertebral compression fractures. Spine (Phila Pa 1976). 2003;28(22):2517–21 discussion 2513.

19. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet. 1996;348(9041):1535–41.

20. Jacobson RE, Palea O, Granville M. Progression of vertebral compression fractures after previous vertebral augmentation: technical reasons for recurrent fractures in a previously treated vertebra. Cureus. 2017;9(10):e1776. https://doi.org/10.7759/cureus.1776.

21. Chen LH, Hsieh MK, Liao JC, Lai PL, Niu CC, Fu TS, et al. Repeated percutaneous vertebroplasty for re-fracture of cemented vertebrae. Arch Orthop Trauma Surg. 2011;131(7):927–33. https://doi.org/10.1007/s00202-011-1236-7.

22. Summa A, Crisi G, Cerasti D, Ventura E, Menozzi R, Ormitti F. Recurrences in cemented vertebrae after percutaneous vertebroplasty and pain relief after a second procedure: a retrospective analysis. Neuroradiol J. 2009;22(2):238–43. https://doi.org/10.1177/177106060902002016.

23. Li YX, Guo DQ, Zhang SC, Liang YK, Mo GY, Li DX, et al. Risk factor analysis for re-collapse of cemented vertebrae after percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP). Int Orthop. 2018;42(9):2131–9. https://doi.org/10.1007/s00264-018-3838-6.

24. Dupuy DE, Palmer WE, Rosenhal D. Vertebral fluid collection associated with vertebral collapse. AJR Am J Roentgenol. 1996;167(6):1535–8. https://doi.org/10.2214/ajr.167.6.8956592.

25. Naul LG, Peet GJ, Maupin WB. Avascular necrosis of the vertebral body: MR imaging. Radiology. 1989;171(2):219–22. https://doi.org/10.1148/radiology.171.2.5440663.

26. Teng MM, Mei CJ, Wei LC, Luo CB, Liiing YC, Chang FC, et al. Kyphosis correction and height restoration effects of percutaneous vertebroplasty. AJNR Am J Neuroradiol. 2003;24(9):1893–900.

27. Liebschner MA, Rosenberg WS, Keaveny TM. Effects of bone cement volume and distribution on vertebral stiffness after vertebroplasty. Spine (Phila Pa 1976). 2001;26(14):1547–54. https://doi.org/10.1097/00007632-200107150-00009.

28. Klazen CA, Venmans A, de Vries J, van Rooij WJ, Janssen FH, Blonk MC, et al. Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II. J Neurol Orthop Med. 2010;31(10):1447–50. https://doi.org/10.3174/ajnr.A2148.

29. Villanara ML, Bellaize AJ, Harrigan TP, Crompton PA, Kurtz SM, Eddin AA. The biomechanical effects of kyphoplasty on treated and adjacent non-treated vertebral bodies. J Spinal Disord Tech. 2005;18(11):894–91. https://doi.org/10.1097/00007694.200512.00000.

30. Buchbinder R, Johnston RV, Rischin KJ, Homick J, Jones CA, Golmohammadi K, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture: Cochrane Database Syst Rev. 2018;7:CD006549.

31. Finnane CE, de Vries J, Lodder F, Venmans A, Schoemaker MC, Smets AJ, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018;361:k1551.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.